- Home
- GRRR vs ALDX Comparison
GRRR vs ALDX Comparison
Compare GRRR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRRR | ALDX |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.9M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GRRR | ALDX |
|---|---|---|
| Price | $11.26 | $5.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $18.00 | $9.50 |
| AVG Volume (30 Days) | 738.3K | ★ 1.6M |
| Earning Date | 11-17-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,747,682.00 | N/A |
| Revenue This Year | $36.15 | N/A |
| Revenue Next Year | $68.68 | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.86 | N/A |
| 52 Week Low | $10.85 | $1.14 |
| 52 Week High | $44.15 | $7.20 |
Technical Indicators
Market Signals| Indicator | GRRR | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.59 | 53.77 |
| Support Level | $11.60 | $4.98 |
| Resistance Level | $12.59 | $5.75 |
| Average True Range (ATR) | 0.75 | 0.47 |
| MACD | -0.17 | 0.07 |
| Stochastic Oscillator | 0.98 | 75.07 |
Price Performance
Historical ComparisonAbout GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.